Maurizio Fava, MD Linkedin Team icon

Member, Scientific Advisory Board Psychiatrist-in-Chief of the Massachusetts General Hospital (MGH)

Dr. Maurizio Fava is Psychiatrist-in-Chief of the Massachusetts General Hospital (MGH), director, Division of Clinical Research of the MGH Research Institute, executive director of the Clinical Trials Network and Institute, (MGH), associate dean for clinical and translational research and the Slater Family Professor of Psychiatry at Harvard Medical School.

Dr. Fava is a world leader in the field of depression. He has edited eight books and authored or co-authored more than 800 original articles published in medical journals with international circulation, articles which have been cited more than 80,000 times in the literature and with an h index of over 140. Dr. Fava obtained his medical degree from the University of Padova School of Medicine and completed residency training in endocrinology at the same university. He then moved to the United States and completed residency training in psychiatry at MGH. He founded and was director of the hospital’s Depression Clinical and Research Program from 1990 until 2014. Under Dr. Fava’s direction, the Depression Clinical and Research Program became one of the most highly regarded depression programs in the country, a model for academic programs that link, in a bi-directional fashion, clinical and research work. In 2007, he also founded and is now the executive director of the MGH Psychiatry Clinical Trials Network and Institute, the first academic CRO specialized in the coordination of multi-center clinical trials in psychiatry.

Member, Scientific Advisory Board
Psychiatrist-in-Chief of the Massachusetts General Hospital (MGH)
Dr. Fava has been successful in obtaining funding as principal or co-principal investigator from both the National Institutes of Health and other sources for a total of more than $120 million. Dr. Fava’s prominence in the field is reflected in his role as the co-principal investigator of STAR*D, the largest research study ever conducted in the area of depression, and of the RAPID Network, the NIMH-funded series of studies of novel, rapidly-acting antidepressant therapies.
Dr. Fava has received several awards during his career and is on the editorial board of five international medical journals. Since 1990, Dr. Fava has also mentored more than 50 trainees who have gone on to become lead investigators in the area of psychiatry. He has developed with Dr. David Schoenfeld a novel design (with over five patents) to address the problem of excessive placebo response in drug trials and to markedly reduce sample size requirements for these trials. In 2009, Dr. Fava received the A. Clifford Barger Excellence in Mentoring Award from Harvard Medical School, and in 2013 the John T. Potts, Jr., MD Faculty Mentoring Award from Massachusetts General Hospital. He is also the former President of the American Society of Clinical Psychopharmacology.
Dr. Fava is a well-known national and international lecturer, having given more than 300 presentations at national and international meetings.

Robert Barrow

Chief Executive Officer and Board Director

Miri Halperin Wernli, PhD

Executive President and Board Director

Cynthia Hu, JD

Chief Legal Officer & Corporate Secretary

Daniel R Karlin, MD MA

Chief Medical Officer

Dave Guebert

Chief Financial Officer

Robert Malenka, MD PhD

Chairman of the Scientific Advisory Board, Nancy Friend Pritzker Professor in Psychiatry and Behavioral Sciences at Stanford University

Peter Bergethon, MD

Member, Scientific Advisory Board VP, Head of Quantitative & Clinical Technologies, Biogen, Inc.

Robert Dworkin, PhD

Professor of Anesthesiology and Perioperative Medicine, Neurology, and Psychiatry at University of Rochester

Maurizio Fava, MD

Member, Scientific Advisory Board Psychiatrist-in-Chief of the Massachusetts General Hospital (MGH)

Maria A Oquendo, MD PhD

Ruth Meltzer Professor and Chairman of Psychiatry at University of Pennsylvania, Psychiatrist-in-Chief at the Hospital of the University of Pennsylvania

Bryan L Roth, MD PhD

Professor of Pharmacology, University of North Carolina School of Medicine; Director of the National Institute of Mental Health Psychoactive Drug Screening Program

Kenneth Alper, MD

Clinical Associate Professor of Psychiatry and Neurology at the New York University School of Medicine

Peter Gasser, MD

Clinical Advisor

Stanley D Glick, MD PhD

Scientific Advisor

Matthew W Johnson, PhD

Clinical Advisor

Kim PC Kuypers, PhD

Scientific Collaborator & Advisor

Matthias Liechti, MD PhD

Scientific Collaborator & Advisor

Sarah McCallum, PhD

Associate Professor of Neuroscience and Experimental Therapeutics (DNET) at Albany Medical College

Natalie Wheeler, PhD

Medical Science Liaison with Dova Pharmaceuticals

John Rotrosen, MD

Professor of Psychiatry with New York University’s Langone’s Department of Psychiatry

Carol Vallone

Chair of the Board of Directors, Chair of Compensation Committee, Member of Audit/Finance Committee

Andreas Krebs

Vice Chair of the Board of Directors, Chair of Nomination and Governance Committee, Member of Audit/Finance Committee

Sarah Y Vinson, MD

Board Director, Member of Compensation, Nomination, and Governance Committees

Brigid Makes

Board Director, Chair of Audit/Finance Committee, Member of Compensation Committee, Member of Nomination and Governance Committee

JR Rahn

Co-Founder

Stephen L Hurst, JD

Co-Founder

Scott Freeman, MD

Co-Founder

Leonard Latchman

Co-Founder

Carrie Liao, CPA

VP, Corporate Controller & Accounting Principal